Navigation Links
Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial
Date:9/24/2009

carboplatin clinical trial for patients with metastatic melanoma, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
2. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
3. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
4. Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... -- CytRx Corporation (NASDAQ: CYTR ), a ... that data regarding the Company,s Phase 2b global clinical ... tissue sarcoma (STS) will be presented in a moderated ... (CTOS) Annual Meeting which is being held October 15-18, ... the longer than expected survival of patients in the ...
(Date:10/16/2014)...  One of California,s most ... the Patient Advocate — this week recognized Kaiser Permanente,s ... state for the seventh consecutive year. The ... and Kaiser Permanente Southern California are the only health ... a four-star rating — the highest possible — for ...
(Date:10/16/2014)... YORK , Oct. 16, 2014 Curtis ... organizer is under 3 weeks away from hosting their co-located ... and Oral Drug Formulation Innovations Summit taking ... San Diego, CA. November,s ... development organizations in streamlining the bioequivalence testing process, as ...
Breaking Medicine Technology:CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 2CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 3CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 4CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 5CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 6Kaiser Permanente's California Health Plans Rated Highest for Quality for Seventh Consecutive Year 2Kaiser Permanente's California Health Plans Rated Highest for Quality for Seventh Consecutive Year 3Simplifying the Bioequivalence Testing Process and Optimizing Oral Formulation Development via Unifying the Global Life Science Community this November in San Diego 2
... July 14 ERT (Nasdaq: ERES ) announced today that ... August 9, 2010 , after the market closes. After the release, the Company ... , , , ... participants should dial 1-800-860-2442 when calling within the United States or ...
... , HONOLULU , July 14 EnVivo ... on Alzheimer,s Disease (ICAD) results from its proprietary gamma-secretase modulator ... reduced amyloid plaque buildup which is believed to be a ... inflammation associated with Alzheimer,s disease. , ...
Cached Medicine Technology:ERT to Announce Second Quarter 2010 Results on August 9, 2010 2EnVivo Pharmaceuticals Announces Significant Results from GSM Transgenic Mouse Model for Alzheimer's Disease 2
(Date:10/20/2014)... USA (PRWEB) October 20, 2014 Do ... track interventions? Here comes a wonderful app Metassessor for ... app development company helped its client “Intervention Development ... efficiently. The app is designed for iOS 4.3 or ... touch. This app is optimized for iPhone 5. It ...
(Date:10/19/2014)... 2014 Dr. Babatunde Osotimehin, Executive Director ... of a ceasefire agreement that is expected to lead ... who were kidnapped from the north-eastern Nigerian town of ... long enough, and it is high time they are ... Osotimehin. , "We owe it to these girls to ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides ... its latest designs of 2014 mother of the ... outfits are offered with big discounts, up to 70% ... 30 can enjoy this special offer. , Owing ... has become one of the leading brands in the ...
(Date:10/19/2014)... SUNDAY, Oct. 19, 2014 (HealthDay News) -- New stem ... eventually lead to new treatments, a new study suggests. ... functioning human intestinal tissue in a lab dish. They ... model for studying intestinal disorders, according to the researchers. ... many diseases and conditions that can cause intestinal failure, ...
(Date:10/19/2014)... Nearly 9,000 transvaginal mesh lawsuits ( ... Johnson’s Ethicon unit have now been centralized in New ... are continuing to move forward, Bernstein Liebhard LLP reports. ... over products part of Ethicon Inc.’s line of Gynecare ... 11th, 2014, which showed an additional 1,600 claims now ...
Breaking Medicine News(10 mins):Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 4
... 16 (HealthDay News) -- Women with rheumatoid arthritis or ... hoped for, according to a new study. These ... cause fertility problems and miscarriage, researchers said. Lupus ... and organs. Rheumatoid arthritis leads to painful joint inflammation. ...
... HealthDay Reporter , WEDNESDAY, Feb. 15 (HealthDay News) -- ... of blood clots in people undergoing certain cancer treatments, ... treated with chemotherapy, they have an increased risk of ... dangerous, and have the potential to cause heart attacks ...
... Denise Mann HealthDay Reporter , WEDNESDAY, Feb. ... also help problem drinkers cut their alcohol consumption, a ... drug curbs drinking is not fully understood, but its ... of sadness and nausea, thereby blunting the pleasurable effects ...
... HealthDay Reporter , WEDNESDAY, Feb. 15 (HealthDay News) -- ... require driver,s education before getting a license, about one-third ... half fail to undergo any formal behind-the-wheel training. ... records were especially unlikely to have received driver,s ed ...
... 15, 2012 California reported the largest decline in drunk-driving ... to recent statistics, and a $232,000 grant from the California ... Safety Administration to UC Irvine,s Health Education Center is ... with the RADD College DUI Awareness Program, UCI has organized ...
... -- Takemi Tanaka, Ph.D., of Thomas Jefferson University,s School ... , received a $50,000 grant toward her breast cancer research, ... for Breast and Cervical Cancer Research" initiative. The ... who choose to contribute all or part of their state ...
Cached Medicine News:Health News:Lupus, Rheumatoid Arthritis Linked to Fertility Woes, Miscarriage 2Health News:New Blood Thinner May Prevent Blood Clots During Cancer Treatment 2Health News:New Blood Thinner May Prevent Blood Clots During Cancer Treatment 3Health News:Stop-Smoking Drug May Also Curb Problem Drinking 2Health News:Many U.S. Teens Hit the Road Without Driver's Ed: Survey 2Health News:Many U.S. Teens Hit the Road Without Driver's Ed: Survey 3Health News:UCI leads multicampus collaboration to reward use of designated drivers 2Health News:Taxpayers give back for cancer: Jefferson researcher awarded 'Refunds for Research' grant 2
... fixation. Completely resorbable, it presented surgeons with ... the most thoroughly proven product of its ... with system enhancements that make it even ... system means that application of this proven ...
... The intra-operative MR system ... intra-operative tool for radiologists ... goal of the system ... valuable adjunct to standard ...
... ultrasound A-scan Sonomed-315 is intended for visualization ... detection of midline shifts in the brain, ... and easy to use, the Sonomed-315 offers ... A-scanning mode allows to identify the anatomic ...
... With Plasmaseal's Proteus device the two steps ... is injected into Proteus' single use disposable ... base unit. The operator touches a button, ... is separated by centrifugation. Then the integral ...
Medicine Products: